0KBU.LSE Omeros Corporation
- Market cap
- -
- P/E
- 5.6x
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 0KBU.LSE undervalued?
Graham numberThe Graham number of Omeros Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Omeros Corporation fundamental analysis
No fundamental analysis for Omeros Corporation yet.
Omeros Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also deve…
Full company profileFinancial statements of Omeros Corporation are not available yet.
Omeros Corporation dividends
Omeros Corporation has not paid dividends in the last 4 fiscal years.
Who owns Omeros Corporation
- Insiders 4.08%
- Institutions 51.73%
- Public & others 44.19%
- Free float 69.3M
Omeros Corporation company profile
- Company name
- Omeros Corporation
- Ticker
- 0KBU.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 175
- Fiscal year end
- December
- Address
- The Omeros Building, Seattle, WA, United States, 98119
- Phone
- 206 676 5000
- Website
- omeros.com
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Omeros Corporation management
9- Dr. Gregory A. Demopulos M.D.Co-Founder, Chairman, CEO & President · born 1959
- Mr. David J. BorgesVP of Finance, Chief Accounting Officer & Treasurer · born 1965
- Mr. Peter B. Cancelmo J.D.VP, General Counsel & Corporate Secretary · born 1979
- Dr. Pamela Pierce Palmer M.D., Ph.D.Co-Founder · born 1963
- Dr. George A. Gaitanaris M.D., Ph.D.Chief Scientific Officer & VP of Science · born 1957
- Mr. Peter W. WilliamsVice President of Human Resources · born 1968
- Dr. Catherine A. Melfi Ph.D.Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems · born 1959
- Mr. David W. GhesquiereVP & Chief Business Development Officer · born 1967
- William E. WoodmanVP & Chief Commercial Officer